Last reviewed · How we verify

NCT03506997: PERSEUS1

Trial of Pembrolizumab in Metastatic Castration Resistant Prostate Cancer

Status unknown Phase 2 Last updated 22 July 2020
What this trial tests

Phase 2 trial testing Pembrolizumab in Castration-resistant Prostate Cancer in 100 participants. Status unknown.

Timeline
27 November 2018
Primary endpoint
1 September 2023
1 September 2025

Quick facts

Lead sponsorInstitute of Cancer Research, United Kingdom
PhasePhase 2
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment100
Start date27 November 2018
Primary completion1 September 2023
Estimated completion1 September 2025
Sites1 location across United Kingdom

Drugs / interventions tested

Conditions studied

Sponsor

Institute of Cancer Research, United Kingdom

Who can join

18 and older, male only, with Castration-resistant Prostate Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

PERSEUS1 is an open-label, single arm, phase II trial evaluating the efficacy of Pembrolizumab in metastatic castration resistant prostate cancer (mCRPC) patients (Part A) with a biomarker enrichment stage (Part B) if efficacy is shown in part A.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic.
    Chan TA, Yarchoan M, Jaffee E, Swanton C, et al · · 2019 · cited 2009× · PMID 30395155 · DOI 10.1093/annonc/mdy495
  2. Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
    Naimi A, Mohammed RN, Raji A, Chupradit S, et al · · 2022 · cited 350× · PMID 35392976 · DOI 10.1186/s12964-022-00854-y
  3. Is There a Role for Immunotherapy in Prostate Cancer?
    Rizzo A, Mollica V, Cimadamore A, Santoni M, et al · · 2020 · cited 68× · PMID 32911806 · DOI 10.3390/cells9092051
  4. Programmed death receptor (PD-)1/PD-ligand (L)1 in urological cancers : the "all-around warrior" in immunotherapy.
    Liu Q, Guan Y, Li S. · · 2024 · cited 50× · PMID 39223527 · DOI 10.1186/s12943-024-02095-8
  5. Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives.
    Rebuzzi SE, Rescigno P, Catalano F, Mollica V, et al · · 2022 · cited 40× · PMID 35267553 · DOI 10.3390/cancers14051245
  6. The Immunotherapy and Immunosuppressive Signaling in Therapy-Resistant Prostate Cancer.
    Xu P, Wasielewski LJ, Yang JC, Cai D, et al · · 2022 · cited 29× · PMID 35892678 · DOI 10.3390/biomedicines10081778
  7. Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review.
    Maekawa S, Takata R, Obara W. · · 2024 · cited 27× · PMID 38339274 · DOI 10.3390/cancers16030523
  8. Immune checkpoint inhibitors in mCRPC - rationales, challenges and perspectives.
    Taghizadeh H, Marhold M, Tomasich E, Udovica S, et al · · 2019 · cited 25× · PMID 31646092 · DOI 10.1080/2162402x.2019.1644109

Verify or expand the search:

Other trials of Pembrolizumab

Trials testing the same drug.

Other recruiting trials for Castration-resistant Prostate Cancer

Currently open trials in the same condition.

Other Institute of Cancer Research, United Kingdom trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03506997.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing